Merck KGaA Enters Research Agreement With Artios on Precision Oncology Treatments
December 03 2020 - 4:03AM
Dow Jones News
By Joshua Kirby
Merck KGaA said Thursday that it is to collaborate with U.K. DNA
damage-response company Artios Pharma on research to discover and
develop multiple precision-oncology drugs.
Under the three-year agreement, Artios will receive $30 million
in up-front and near-term payments, Merck said. The German
pharmaceutical company added that it will have the right to opt
into development and commercialization of compounds on up to eight
targets. Artios could then receive a further $860 million in
milestone payments, as well as up to double-digit royalties on net
sales of each product.
The companies will together use Artios's proprietary
nuclease-targeting discovery platform to identify multiple targets
for precision cancer-treatment candidates, Merck said. The terms of
the agreement don't cover Artios's lead programs, for which it will
retain all rights.
Write to Joshua Kirby at joshua.kirby@dowjones.com;
@joshualeokirby
(END) Dow Jones Newswires
December 03, 2020 03:48 ET (08:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
